US OptionsDetailed Quotes

EYPT241018C10000

Watchlist

0.08
-0.06-42.86%

15min DelayClose Oct 4 16:00 ET

0.09High0.08Low

EyePoint Pharmaceuticals Stock Discussion

Everyday 100 dollars

May 6 23:08

$EyePoint Pharmaceuticals (EYPT.US)$ I’m here

Jaguar8

May 6 06:36

$EyePoint Pharmaceuticals (EYPT.US)$
NEWS
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint

frogoracletrading

May 6 06:19

$EYPT Support / Resistance Levels

Here are the levels to watch after the halt.
Larger Image: tradingview.com...
$EyePoint Pharmaceuticals (EYPT.US)$

Trytosaveabit

May 6 06:01

Look out below?

$EyePoint Pharmaceuticals (EYPT.US)$ EyePoint Pharmaceuticals Inc: Trial Did Not Meet Pre-Specified Primary Endpoint

Trytosaveabit

May 6 05:58

T1 News halt

$EyePoint Pharmaceuticals (EYPT.US)$

Moomoo AI

Mar 10 21:07

The downgrade indicates increased forecast losses for EyePoint Pharmaceuticals this year, suggesting potential issues within the company. The slower growth in revenues compared to the wider market may also cause investors to exercise more caution towards the company.

Revenue Downgrade: Here's What Analysts Forecast For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Moomoo AI

Feb 20 04:32

Despite minimal revenue growth and losses, the company's share price has surged, casting doubts on the sustainability of this trend. The company's recent positive performance may suggest real business momentum, but investors should heed warning signs.

While EyePoint Pharmaceuticals (NASDAQ:EYPT) Shareholders Have Made 700% in 1 Year, Increasing Losses Might Now Be Front of Mind as Stock Sheds 4.5% This Week

JuliaBiswas

Feb 5 04:12

Who is the winner today, after the poditive data announced on 03 Feb
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$

Stock_Drift

Jan 5 19:53

$EyePoint Pharmaceuticals (EYPT.US)$
📊⚡️📊

Moomoo AI

Jan 3 08:14

Investors banking on improved revenue performance due to high P/S ratio may face disappointment due to the negative growth outlook. This scenario poses a substantial risk to shareholders' investments and potential investors may end up paying a hefty premium.

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Price Is Out Of Tune With Revenues

No comment yet